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Abstract
Background: Many formulae of traditional Chinese medicines (TCMs) have been used for antiasthma treatment
dating back many centuries. There is evidence to suggest that TCMs are effective as a cure for this allergenic
disease administered via gastric tubes in animal studies; however, their efficacy, safety and side effects as an
asthmatic therapy are still unclear.
Methods: In this study, guinea pigs sensitized with ovalbumin (OVA) were used as an animal model for asthma
challenge, and the sensitization of animals by bronchial reactivity to methacholine (Mch) and the IgE concentration
in the serum after OVA challenge were estimated. Complex traditional Chinese herbs (CTCM) were administered to
the animals by nebulization, and the leukocytes were evaluated from bronchoalveolar lavage fluid (BALF).
Results: The results showed that inhalation of CTCM could abolish the increased lung resistance (13-fold increase)
induced by challenge with OVA in the early asthmatic response (EAR), reducing to as low as baseline (1-fold).
Moreover, our results indicated higher IgE levels (range, 78-83 ng/ml) in the serum of sensitized guinea pigs than
in the unsensitized controls (0.9 ± 0.256 ng/ml). In addition, increased total leukocytes and higher levels of
eosinophils and neutrophils were seen 6 hours after challenge, and the increased inflammatory cells were reduced
by treatment with CTCM inhalation. The interleukin-5 (IL-5) level in BALF was also reduced by CTCM.
Conclusion: Our findings indicate a novel method of administering traditional Chinese medicines for asthma
treatment in an animal model that may be more effective than traditional methods.
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Background
Bronchial asthma is a complex syndrome with many
clinical symptoms. It is characterized by variable airflow
obstruction, airway hyperresponsiveness and inflamma-
tion [1,2]. Provocation of the airway by inhaled allergens
is followed by bronchospasm and airway smooth muscle
thickening, and accumulation of eosinophils in mucosa
and in bronchoalveolar lavage also occurs [1,3]. In addi-
tion, according to analyses of bronchial biopsies and
lavage samples removed from allergen-exposed
asthmatics, contributing to the earlier asthmatic
response (EAR) and late asthmatic response (LAR) after
allergen challenge [4,5], IgE-dependent activation of
mast cells is present with degranulation and subsequent
release of several mediators such as histamine, prosta-
noids and leukotrienes into the lumen of the airway. It
is generally agreed that the EAR reaches a peak at about
5-30 min after challenge and lasts for around 2 hours,
and in more than 50% of atopic asthmatic patients, the
EAR is followed by the LAR, which occurs 4-12 h after
challenge and lasts for several hours, even up to a cou-
ple of days [6]. The development of allergen-induced
airway hyperresponsiveness is correlated with the LAR
[7], in which an increase in the quantity of airway
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observed in induced sputum [4,6]. A number of small
animal models such as mice, rats and guinea pigs have
been developed for asthma study, in which the LAR
occurs in the airway of sensitized animals after exposure
to antigens. Of the animal models, the guinea pig is gen-
erally the preferred model because the responses to a
variety of contractile and relaxant substances are similar
to those of humans [8,9].
For the treatment of asthma, sodium cromoglycate
and b2-adrenoceptor agonist inhibit the EAR. On the
other hand, both the LAR and associated airway hyper-
responsiveness are inhibited by sodium cromoglycate
and corticosteroids, not by b2-adrenoceptor agonists
[10-12]. In addition, in most cases, mild-to-moderate
asthma can be controlled by inhalational steroids; how-
ever, long-term steroid therapy is often associated with
multiple side effects that have long-term repercussions
on one’s health [13]. In contrast to western medicines,
Chinese herbs have been used to treat asthma for many
centuries, some of which have been proven to inhibit
the EAR and LAR in asthma patients subjected to speci-
fic allergens [8,14-16]. Freeze-dried powder of a tradi-
tional Chinese medicine was administered via a gastric
tube before or after challenge in this study. The results
showed that the Chinese medicine attenuated the
increased respiratory resistance and the amount of eosi-
nophilia induced by the allergens [8,14-16]; however, the
mechanisms are unclear. In this study, a formula of
complex traditional Chinese medicines (CTCM) was
used. This formula contains eight herbs and has been
generally used to treat asthmatic patients in Chinese
medicine clinics. The CTCM was delivered by inhala-
tion, which we expected to have a better effect than oral
administration as the drug can directly and rapidly
reach the airways.
In this study, we evaluated the effects of CTCM on
the change in the mean pulmonary resistance and the
inflammatory responses of the airway in ovalbumin
(OVA)-sensitized guinea pigs. The CTCM was nebulized
and inhaled autonomically by the animals under
anesthesia. The inhalation route is new for CTCM. The
effect of local treatment with CTCM on the asthmatic
response in sensitized guinea pigs was then investigated.
Methods
Sensitization and challenge of animals
The study protocol was approved by the Institutional
Review Board of the National Cheng Kung University.
Sensitization of the guinea pigs was performed as
described in previous studies [17,18] with some modifi-
cation. Briefly, specific pathogen-free Dunkin-Hartley
male guinea pigs (GP) weighing 400-600 g, obtained
from the National Laboratory Animal Center, Taipei,
Taiwan, were used in this study. The animals were
actively IgE-sensitized to OVA (grade VI; Sigma-Aldrich,
St. Louis, MO, USA). On day one, 100 μg OVA with 10
mg of aluminum hydroxide (Al(OH)3)g e li n0 . 5m lo f
normal saline were injected intraperitoneally. A booster
sensitization (50 μg of OVA and 5 mg of aluminum
hydroxide gel in 0.25 ml normal saline) was adminis-
t e r e do nd a y7 .T h es e n s i t i z e dg u i n e ap i g sw e r et h e n
exposed to an aerosol containing 1% OVA (w/v) for 20
sec on day 14. Animals were anesthetized with urethane
(2 g/kg i.p.), intubated, and challenged by inhalation of
nebulized 1% OVA (w/v) for 20 sec on day 21. Unsensi-
tized guinea pigs were treated in the same way with nor-
mal saline.
Preparation of the Chinese herbal formula
In this study, we used a CTCM formula that is used by
traditional Chinese medical physicians for the treatment
of asthmatic patients. The composition of the CTCM
was similar to the xiao-qing-long-tang (XQLT) formula,
a formula of Chinese medicine that has been proven to
suppress the EAR and LAR in sensitized guinea pigs via
oral administration [14]. There are eight common Chi-
nese herbs in this CTCM: Ephedrae herba (stem of
Ephedrae sinica Stapf, 18.75 g), Paeoniae radix (root of
Paeoniae lactiflora Pallas, 18.75 g), Glycyrrhizae radix
(root and rhizome of Glycyrrhiza uralensis Fischer,
18.75 g), Cinnamonomi ramulus (cortex of Cinnamo-
mum cassia Blume, 18.75 g), Asari herba cum radice
(whole plant of Asarum sieboldii Miq, 18.75 g), bitter
apricot seed ( Prunus armeniaca (Magnoliaceae), 18.75
g), Common perilla stem (Perilla frutescens (Labiatae),
18.75 g), and Ledebouriella root (Saposhnikovia divari-
cate (Apiaceae), 18.75 g). The herbs were purchased
from a government-approved herbal company, Hong
Cheng Chinese Medicine (Tainan, Taiwan). All air-dried
herbs were submerged in 800 ml distilled water for 30
min, then heated to boiling point and maintained at
about 103°C for 15 min. The resulting extract was fil-
tered through a 0.45-mm filter and concentrated to
approximately 350 ml. The concentrated extract was
finally lyophilized to yield 21 g dried powder, which was
maintained at 4°C for storage. The dried extract was dis-
solved in saline before use. For inhalation, three concen-
trations (0.03, 0.06 and 0.09 g/ml) of CTCM were
tested, and the latter two concentrations showed a simi-
lar inhibition effect. Therefore, a CTCM concentration
of 0.06 g/ml was used in this study.
The airway hyperresponsiveness (AHR) of Mch
This study examined the dysfunction underlying AHR,
including two major physiopathological mechanisms:
hypersensitivity and hyperreactivity. Hypersensitivity is a
shift to the left of the bronchoconstrictor dose-response
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curve. The bronchial hyperresponsiveness of guinea pigs
to Mch was recorded to assess the sensitization of the
animals. The underlying contributors to airway respon-
siveness were measured on the basis of the respiratory
system resistance to saline and increasing intravenous
doses of Mch, as per the method described elsewhere in
detail by others [19-21] with some modification. Briefly,
to achieve optimal sensitization, we used increasing
doses of Mch, at 12.5, 50, 100, 250, and 500 μg/kg.
Experimental design and administration
Respiratory resistance (RL) was measured before treat-
ment as a baseline control. RL was subsequently
recorded after challenge eve r y5m i ni nt h ef i r s th o u r
and every 30 min in the following 5 hours. The guinea
pigs were randomly divided into four groups:
1) NSGP (n = 10): unsensitized GP challenged with
OVA.
2) SGP (n = 10): sensitized GP challenged with OVA.
3) MSGP (n = 10): sensitized GP treated with 0.06 g/
ml CTCM for 5 min by nebulization, followed by OVA
challenge (at 5 min after CTCM nebulization).
4) SMGP (n = 10): sensitized GP challenged with
OVA, followed by treatment with 0.06 g/ml CTCM for
5 min by nebulization (at 10 min after OVA challenge).
Measurement of airway responses to OVA challenge
Guinea pigs were anesthetized with urethane (2 g/kg; i.
p.), tracheostomized, and cannulated with polyethylene
tubing (PE210; Scientific Commodities, Lake Havasu
City, AZ, USA), then a catheter was advanced through
the mouth into the lower end of the esophagus. Pleural
pressure was measured via the esophageal catheter. The
lateral pressure in the trachea, transpulmonary pressure
( t h ed i f f e r e n c eb e t w e e nt h et racheal and pleural pres-
sure), and RL were measured as described in a previous
study [22]. A pneumotachograph (Series 1110; Hans
Rudolph, Shawnee, KS, USA) connected to the proximal
end of the endotracheal tube was used to measure RL.
The respiratory volume was obtained by digital integra-
tion of the flow signal, and RL was calculated from the
transpulmonary pressure and flow rates at isovolumetric
points [22]. Samples of 5-10 breaths were analyzed for
each determination of RL. In addition, we measured the
underlying contributors to airway responsiveness,
including airway reactivity (i.e., the slope of the increase
in the mean pulmonary flow resistance [RL]f o rag i v e n
increase in Mch dose), airway sensitivity (i.e., the lowest
dose of Mch that produced bronchoconstriction), and
the maximum inducible bronchoconstriction (maximum
RL). These components of airway responsiveness were
measured based on the response of RL to saline and
increasing intravenous doses of Mch.
IgE in serum
Blood was withdrawn from the guinea pigs from the
heart 6 hr after challenge. The IgE level specific to OVA
in the serum was estimated using commercial ELISA
kits (MARUKO, Nagoya, Japan).
Bronchoalveolar lavage
Bronchoalveolar lavage was performed 6 h after OVA
challenge. Lung lavage was performed gently using 3 ml
of PBS (phosphate-buffered saline) at 37°C. The tracheal
cannula was clamped, and the thorax was massaged for
60 s before the bronchoalveolar lavage fluid (BALF) was
recovered. This process was repeated once. The recov-
ered lavage samples were cooled on ice and centrifuged
at 150 × g for 10 min at 4°C. Approximately 4 mL of
fluid were recovered from each sample of BALF, thus
maintaining a roughly equal amount of BALF among
the treatment groups. The total cell count and cell viabi-
lity were estimated using a hemacytometer and trypan
blue staining. Slides were prepared using a Cytospin
model II (Shandon, Pittsburgh, PA, USA). The differen-
tial cell count was assessed with Liu’s stain. A total of
500 cells were assessed and classified into mononuclear
cells, neutrophils, or eosinophils based on the standard
morphologic criteria.
IL-5 in BALF
IL-5 in BALF supernatant was assessed using commer-
cial ELISA kits (R&D Systems, Minneapolis, MN, USA).
Statistical Analysis
The data from 10 animals in each group were collected,
and the results are expressed as mean ± SEM (standard
error of the mean). Repeated measures ANOVA or one-
way ANOVA was performed to compare the statistical
difference between groups. Differences with P <0 . 0 5
were judged to be significant.
Results
Effects of Mch on the airway
The RL of the guinea pigs was dependent on the dose of
Mch. However, the curve of RL in relation to Mch had a
greater slope for the sensitized animals than that for the
unsensitized animals (Figure 1). Therefore, the results
suggested that the sensitized guinea pigs exhibited
enhanced airway responsiveness to Mch.
IgE in the serum of unsensitized and OVA-sensitized guinea
pigs after challenge
In the OVA-sensitized GP after challenge (with or with-
out CTCM nebulization), the average OVA-specific IgE
in the serum of the sensitized guinea pigs in the SGP
group was 78.0 ± 17.83 ng/ml, and the average IgE
levels of the MSGP and SMGP groups were about 83.4
± 19.57 ng/ml and 81.9 ± 10.79 ng/ml, respectively.
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in the unsensitized control group, which was approxi-
mately 0.9 ± 0.256 ng/ml (Figure 2).
RL of guinea pigs after challenge
The respirator resistance (RL) was monitored at regular
intervals for up to 6 hr after aerosol inhalation of anti-
gens (Figure 3A). Aerosolized OVA caused immediate
bronchoconstriction, which peaked at 15 min among the
sensitized guinea pigs. In the SGP group, inhalation of
OVA increased the RL by 13-fold that of the control. In
addition, the EAR was also exhibited in the SGP group.
The EAR started immediately after OVA challenge and
reached a maximum about 15 min after challenge with
OVA. At any point in time after challenge, the RL in the
SGP group was at least 2-fold that in the NSGP group (P
< 0.01 at 15 min). At around 6 hr after challenge, another
increase in RL of a moderate level was observed.
Effect of CTCM on allergen-induced respiratory resistance
For the animals pre-treated with CTCM (the MSGP
group), RL reduced to the baseline level of the control
group after challenge (Figure 3A). The respirator resis-
tance at each time point from 5 min to 1 h after chal-
lenge was significantly lower in the MSGP group than
in the control SGP group (P < 0.01 at 10, 15, 20 min)
(Figure 3B). On the other hand, as the maximum
increase in RL was observed 15 min after challenge, we
therefore examined the effect of post-treatment with
CTCM 10 min after challenge. Interestingly, the results
showed that for the animals post-treated with CTCM
(SMGP group), CTCM treatment almost completely
impeded the early OVA-induced RL response immedi-
ately (data not shown in Figure 3A as the line of the
SMGP group overlapped with that of the MSGP group).
The RL of the SMGP group was increased at 5 and 10
min, but the increase in RL was attenuated after treat-
ment with CTCM, and RL had decreased to the baseline
levels of the control and MSGP groups 15 min after
challenge (P < 0.01 at 15 min; Figure 3B).
Effect of CTCM on OVA-induced inflammatory cells
infiltration in BALF
We next recovered inflammatory cells from BALF
obtained from the animals at 6 hr. As compared with
the non-immunized group, OVA caused a significant
increase in inflammatory cells in the immunized group
without CTCM treatment (SGP) (Figure 4). There was
also a significant increase of eosinophils at this time
point after OVA challenge, while CTCM treatment,
either before or after OVA challenge, had an inhibitive
effect on eosinophil infiltration in BALF, as shown in
Figure 5. As compared with the immunized group
(SGP), our results showed that CTCM treatment sig-
nificantly reduced the increase in eosinophils in BALF
Figure 1 Airway responsiveness methods. Pulmonary airflow
resistance (RL) was measured in response to increasing doses
of intravenous methacholine (Mch). Using the resulting RL-Mch
dose-response curve, indices of airway reactivity (Slope RL), airway
sensitivity, the lowest dose producing bronchoconstriction (Break RL)
and the maximal degree of bronchoconstriction (Max RL) were
measured (repeated measures ANOVA with a Mauchly post-hoc test,
sensitized vs. unsensitized; **P < 0.01).
Figure 2 IgE in the serum of guinea pigs. Statistical
significance (one-way ANOVA with a Duncan post-hoc test, **P
< 0.01) represents a comparison between the sensitized
groups (SGP, MSGP and SMGP) and the control group (NSGP).
Each column represents the mean of the data from 10 animals and
the restical bars represent the standard deviation. NSGP:
unsensitized animals with challenge; SGP: sensitized animals with
challenge; MSGP: sensitized animals with CTCM treatment 5 min
before challenge; SMGP: sensitized animals with CTCM treatment 10
min after challenge.
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treatment also inhibited the increase in neutrophils (P
< 0.01) in both the CTCM pre- and post-treated
groups.
IL-5 in the BALF of the guinea pigs
The average IL-5 level in the BALF of the unsensitized
guinea pigs (NSGP group) was about 43 pg/ml, and the
average IL-5 level of the SGP group was increased by
OVA to 135 pg/ml. In the MSGP and SMPG groups,
the average IL-5 levels were decreased by CTCM inhala-
tion to 64 pg/ml and 88 pg/ml, respectively (Figure 6).
Figure 3 The effect of CTCM on the change in the respiratory
resistance (ratio) after allergen challenge in OVA-sensitized
asthmatic guinea pigs. (A) Overview of the 6-hr period.
Comparison between the NSGP, SGP and MSGP groups. (B)
Comparison of the different groups of sensitized animals in the first
hour (repeated measures ANOVA with a Mauchly post-hoc test,
sensitized vs. unsensitized; **P < 0.01). NSGP: unsensitized animals
with challenge; SGP: sensitized animals with challenge; MSGP:
sensitized animals with CTCM treatment 5 min before challenge;
SMGP: sensitized animals with CTCM treatment 10 min after
challenge. Each point represents the mean of the data from 10
animals and the restical bars represent standard deviation.
Figure 4 The effect of CTCM on the change in the total
leukocyte cell number 6 hr after allergen challenge in OVA-
sensitized asthmatic guinea pigs. Each column represents the
mean of the data from 10 animals and the restical bars represent
standard deviation (one-way ANOVA with a Duncan post-hoc test,
**P < 0.01). NSGP: unsensitized animals with challenge; SGP:
sensitized animals with challenge; MSGP: sensitized animals with
CTCM treatment 5 min before challenge; SMGP: sensitized animals
with CTCM treatment 10 min after challenge.
Figure 5 The effects of CTCM on the changes in differential
cell counts after allergen challenge in OVA-sensitized
asthmatic guinea pigs. CTCM treatment before or after OVA
challenge decreased the cells numbers of eosinophils and
neutrophils (MSGP or SMGP vs. SGP; one-way ANOVA with a
Duncan post-hoc test, **P < 0.01). Each group represents the mean
of the data from 10 animals and the restical bars represent standard
deviation. NSGP: unsensitized animals with challenge; SGP:
sensitized animals with challenge; MSGP: sensitized animals with
CTCM treatment 5 min before challenge; SMGP: sensitized animals
with CTCM treatment 10 min after challenge.
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In this study, we used an OVA-sensitized guinea pig
model to investigate the effect of inhalation of CTCM
on the early and late antigen-induced airway responses.
Guinea pigs have been used as an animal model for
asthmatic research for many years. Different sensitiza-
tion processes may induce different severities of anti-
gen reactions. Booster sensitization by an aerosolized
antigen has been widely used in recent years, as this
antigen delivery route is similar to the natural physio-
logical way, and this method can elicit responses
including elevated levels of allergen-specific IgE, eosi-
nophilic airway inflammation, and AHR [8,14-16]. On
the other hand, delivery of medication directly to the
airways has a quicker action than the oral route, as the
drug can act immediately upon the target area. There-
fore, inhalation therapy is generally thought to be the
most effective and safe route in comparison with other
forms of administration of medications for the treat-
ment of asthma.
Bronchial hyperreactivity to both histamine and Mch
has been well established and is used in the clinical
diagnosis of asthma [23,24]. Mch is believed to have lit-
tle or no irritant effect but to act directly on the choli-
nergic receptors innervated in smooth muscle [25]. In
the test of Mch, this nonspecific stimulator induced a
larger RL in the sensitized subjects than the unsensitized
ones. The slope of the dose and RL curve in the sensi-
tized groups shifted to the left, as has been observed in
other studies [26]. The IgE levels in the serum of the
animals in the sensitized groups were also higher than
those in the unsensitized animals. These results sug-
gested that the process of sensitization was successful,
and that a sensitized model was established. Further-
more, there was no significant difference in the IgE level
in the serum between the animals treated with CTCM
(MSGP and SMGP groups) and those without CTCM
treatment (SGP group). This might be due to the guinea
pigs having been sensitized to OVA three times in a
total of 21 days; therefore, specific anti-OVA IgE was
induced to very high levels. In addition, as the CTCM
was applied directly to the airway, it therefore had no
significant effect on the level of serum IgE. The results
showed that the guinea pigs in the CTCM-treated
groups were indeed sensitized and that bronchoconstric-
tion was abolished by CTCM.
Chinese herbs have been used for the treatment of
asthmatic patients for centuries. Most of the Chinese
herbs used for the treatment of bronchial asthma are
either administered orally or through a gastric tube for
research purposes. For example, several studies have
demonstrated the anti-asthmatic effects of traditional
Chinese medicine formulas such as XQLT by adminis-
t e r i n gt h em e d i c i n ev i at h eg a s t r i cr o u t et og u i n e ap i g s
[14-16], and simplified herbal medicine treatment also
reduced several asthma features in a mouse model
[27,28]. Currently, many of the western medicines used
for the treatment of asthma are inhaled. Although sev-
eral CTCM formulas have been shown to relieve asthma
symptoms by oral administration, no study has been
found in the English literature in which CTCM was
administered in inhaled form to validate its efficacy.
Administration of CTCM by inhalation, such as the use
of portable bronchodilator sprays, which are already
widely used in asthma treatment, is convenient and rela-
tively simple. Inhalation it is expected to have a better
effect than oral administration, as the CTCM can
directly and rapidly reach the airways. For practical
application, it is possible to use an aerosol inhaler to
deliver CTCM into the lungs.
In this study, we demonstrated that CTCM adminis-
tered in nebulized form through the intratracheal route
is capable of inhibiting both the early and late asthmatic
responses and the influx of inflammatory cells into the
airways of guinea pigs following bronchial antigen chal-
lenge. The results indicate that this CTCM is a bronch-
oprotective substance and exerts an anti-inflammatory
effect in OVA-sensitized guinea pigs. This is the first
time that Chinese medicines have been used in the
treatment of bronchial asthma by inhalation in an ani-
mal model. The EAR and LAR to OVA challenge in
Figure 6 The effect of CTCM on the change in IL-5. CTCM
treatment before or after OVA challenge reduced IL-5 levels in
the BALF (one-way ANOVA with a Duncan post-hoc test, **P <
0.01: MSGP or SMGP vs. SGP). Each group represents the mean of
the data from 10 animals and the restical bars represent standard
deviation. NSGP: unsensitized animals with challenge; SGP:
sensitized animals with challenge; MSGP: sensitized animals with
CTCM treatment 5 min before challenge; SMGP: sensitized animals
with CTCM treatment 10 min after challenge.
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by CTCM treatment in the present study.
When anti-asthmatic drugs are administered prior to
antigen challenge, sodium cromoglycate inhibits both
the EAR and LAR, whereas both the LAR and associated
airway hyperresponsiveness are inhibited by sodium cro-
moglycate and corticosteroids [29]. Albuterol, a b2-ago-
nist, blocks the EAR but neither inhibits the LAR nor
affects eosinophil infiltration [29]. Dexamethasone inhi-
bits the LAR, but not the EAR, and inhibits the increase
in eosinophils in BALF 24 hr after antigen challenge
[30]. In this study, the effects of CTCM treatment on
antigen-induced airway responses were investigated, and
our results showed inhibition of the increased RL and
eosinophilia by CTCM. We have demonstrated that
nebulized CTCM exerts both a bronchodilator and anti-
inflammatory activity in OVA-sensitized guinea pigs.
Inhalation of CTCM both 5 min before challenge
(MSGP group) and 10 min after challenge (SMGP
group) significantly inhibited the EAR and the increase
of inflammatory cells in the airways, including eosino-
phils and neutrophils. These findings suggest that
CTCM can be used as an anti-asthmatic agent and is
useful for the prevention or treatment of asthma.
Many compounds extracted from herbs have demon-
strated anti-oxidant properties and anti-inflammatory
effects, which can lead to a decrease in allergic tissue
injury. For example, green tea extract has been reported
to have an anti-inflammatory activity that inhibits iNOS
expression by suppressing IFN-g-elicited STAT-1 activa-
tion [31], and aqueous extract of Arbutus unedo L. has
been shown to attenuate carrageenan-induced lung
inflammatory injury, which is associated with the inhibi-
tion of IL-6 production, reduction of STAT-1 and
STAT-3 expression, and downregulation of iNOS and
ICAM-1 mRNA expression [32]. It is still unclear
whether the CTCM used in this study has a similar
mechanism to the mechanisms observed for other her-
bal extracts that possess inhibition properties to tran-
scription factors or have direct effects on pro-
inflammatory genes. This is worthy of further investiga-
tion to explore the mechanisms involved.
Many studies have shown that development of the
LAR is associated with recruitment of eosinophils into
the airway, which presumably cause cellular activation
and bronchoconstriction [33-36]. These reactions are
due to the release of cytotoxic granular-associated pro-
teins by eosinophils, including major basic protein, eosi-
nophil cationic protein, and eosinophil peroxidase,
which have a profound effect on the airway [16,37,38].
Furthermore, eosinophil activation results in the release
of other mediators, such as leukotriene C4 and platelet-
activating factor, which can cause contraction of the air-
way smooth muscles [39,40]. In the present study, an
increase in eosinophils in response to OVA challenge
was observed, and the administration of CTCM inhib-
ited the eosinophilia in OVA-sensitized guinea pigs. IL-5
is an important cytokine for eosinophil development and
activation, and secretion of IL-5 causes eosinophil
recruitment into the airways during the allergic airway
response [41,42]. The results of this study showed that
IL-5 in BALF was induced by OVA, and that the CTCM
could reduce the increased IL-5.
Although the presence of eosinophils in airway inflam-
mation is recognized as an important event, it does not
fully explain the inflammation observed in asthma.
Increased numbers of neutrophils have been found in
patients with acute or persistent asthma compared with
controls [43,44]. Many studies have also reported that
increased neutrophil levels may contribute to exacerba-
tion in asthma patients exposed to allergens, and airway
neutrophils may be associated with asthma severity [45].
Although it is still controversial, there is increasing evi-
dence to support the hypothesis that neutrophils are
important in the pathophysiology of asthma. Our results
also demonstrated that CTCM inhibited the OVA-
induced increase of neutrophils, which suggests that
CTCM inhalation might block neutrophil recreation to
the site of the allergic reaction.
Conclusion
In conclusion, we have demonstrated for the first time
that nebulized CTCM is effective against early-phase air-
flow obstruction in anaesthetized sensitized guinea pigs
challenged by OVA inhalation. The OVA-induced
increases in airway eosinophils and neutrophils and the
increased levels of IL-5 in BALF in the late phase were
also inhibited by nebulized CTCM treatment. Our
results suggest that there may be two anti-asthmatic
mechanisms for CTCM, a bronchodilator effect resulting
from its stimulation of b2-receptors on bronchial
smooth muscles, and an ability to inhibit the increased
IL-5 and eosinophil infiltration into the airway. The pre-
cise mechanism of nebulized CTCM in asthma remains
to be elucidated, but the effect of reducing early and
late antigen-induced airway responses highlights a possi-
ble novel way of administering CTCM for asthma
treatment.
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